Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
151 hedge funds and large institutions have $1.28B invested in Aerie Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 25 closing their positions.
90% more call options, than puts
Call options by funds: $6.69M | Put options by funds: $3.52M
13% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 54
4% more capital invested
Capital invested by funds: $1.23B → $1.28B (+$52.1M)
7% less funds holding
Funds holding: 162 → 151 (-11)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
36% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$28.4M |
| 2 |
O
OrbiMed
New York
|
+$26.4M |
| 3 |
Millennium Management
New York
|
+$24.7M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$22.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$20.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$46.7M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$20.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.7M |
| 4 |
PA
Perceptive Advisors
New York
|
-$13.5M |
| 5 |
WC
Weatherbie Capital
Boston,
Massachusetts
|
-$10M |
AERI Hedge Fund Activity: Q4 2016 in Review
151 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2016, worth a combined $1.28B — up 4.2% from $1.23B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of AERI and 16 opened new positions — a net loss of 9 holders — while 54 trimmed existing stakes and 61 added.
The largest buyer was Deutsche Bank, adding an estimated $28.4M. The largest seller was TPG Group Holdings (SBS) Advisors, exiting entirely with an estimated $46.7M sold.
- 151 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2016, down from 162 in Q3 2016.
- Funds reported $1.28B of Aerie Pharmaceuticals stock for Q4 2016, up 4.2% quarter-over-quarter.
- 16 funds opened new Aerie Pharmaceuticals positions in Q4 2016 and 25 closed out, a net change of -9 holders.
- The largest Aerie Pharmaceuticals buyer in Q4 2016 was Deutsche Bank, an estimated $28.4M added.
- The largest Aerie Pharmaceuticals seller in Q4 2016 was TPG Group Holdings (SBS) Advisors, an estimated $46.7M sold.
Based on aggregated 13F filings for Q4 2016.